

From: [Trials](#)
To: [Ferenc, Christopher B.](#); [Trials](#)
Cc: [Sodikoff, Brian](#); [Megan Raymond](#); [Novo-Semaglutide-IPR@groombridgewu.com](#); [J. Steven Baughman](#)
Subject: RE: IPR2024-00107
Date: Wednesday, May 15, 2024 2:39:26 PM

Counsel,

The Board authorizes Petitioner to file its updated stipulation as an exhibit in this proceeding in accordance with its May 13 e-mail, reproduced below. The Board also authorizes Patent Owner to file a 3-page brief to address discretionary denial issues by no later than Monday, May 20, 2024. The Board also authorizes Petitioner to file a one-page response to Patent Owner's brief addressing discretionary denial issues by Wednesday, May 22, 2024. The Board does not believe a call is necessary at this time.

Regards,
Eric W. Hawthorne
Supervisory Paralegal Specialist
Patent Trial and Appeal Board

From: Ferenc, Christopher B. <christopher.ferenc@katten.com>
Sent: Monday, May 13, 2024 12:32 PM
To: Trials <Trials@USPTO.GOV>
Cc: Sodikoff, Brian <brian.sodikoff@katten.com>; Megan Raymond <megan.raymond@groombridgewu.com>; Novo-Semaglutide-IPR@groombridgewu.com; J. Steven Baughman <steve.baughman@groombridgewu.com>
Subject: IPR2024-00107

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

PTAB,

Petitioners Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. (together "Sun") have filed a stipulation in the District Court in the underlying litigation. This stipulation updates a previously submitted stipulation by Sun made of record in this proceeding (Exhibit 2026). Petitioners request authorization to submit updated stipulation as an exhibit in this proceeding for consideration by the Board.

Patent Owner opposes this request, and requests a call to the extent the Board is inclined to grant it. Patent Owner further requests a 3-page brief to address discretionary denial issues, including the sufficiency of the previous and above-mentioned stipulation in view of Petitioner's refusal to confirm to Patent Owner that it will not contribute to district court litigation on any of the stipulated grounds behind the scenes (e.g., Sun may still pay for experts, participate in expert reports, deposition

preparation, etc. in connection with any of the stipulated grounds).

If the Board is inclined to grant Patent Owner's request for additional briefing, Petitioners request authorization to file a 1-page response.

The parties are available for a call with the Board at the following times: Monday, May 13 from 4-5, or Wednesday, May 15 from 2-3, or otherwise at the Board's convenience.

Regards,
Chris Ferenc
Counsel for Petitioners

Christopher B. Ferenc
Partner

Katten

Katten Muchin Rosenman LLP
1919 Pennsylvania Ave., NW., Suite 800 | Washington, DC 20006
direct +1.202.625.3647
christopher.ferenc@katten.com | katten.com

=====
CONFIDENTIALITY NOTICE:
This electronic mail message and any attached files contain information intended for the exclusive use of the individual or entity to whom it is addressed and may contain information that is proprietary, privileged, confidential and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any viewing, copying, disclosure or distribution of this information may be subject to legal restriction or sanction. Please notify the sender, by electronic mail or telephone, of any unintended recipients and delete the original message without making any copies.
=====

NOTIFICATION: Katten Muchin Rosenman LLP is an Illinois limited liability partnership that has elected to be governed by the Illinois Uniform Partnership Act (1997).
=====